Last reviewed · How we verify
TRO19622
At a glance
| Generic name | TRO19622 |
|---|---|
| Also known as | Olesoxime |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH) (PHASE2)
- Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS (PHASE3)
- A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA) (PHASE2)
- Safety Extension Study of TRO19622 in ALS (PHASE2, PHASE3)
- Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients. (PHASE2)
- Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy (PHASE2)
- Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy (PHASE2)
- Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRO19622 CI brief — competitive landscape report
- TRO19622 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI